- Home
- IGMS vs HBCP Comparison
IGMS vs HBCP Comparison
Compare IGMS & HBCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- HBCP
- Stock Information
- Founded
- IGMS 1993
- HBCP 1908
- Country
- IGMS United States
- HBCP United States
- Employees
- IGMS N/A
- HBCP N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- HBCP Banks
- Sector
- IGMS Health Care
- HBCP Finance
- Exchange
- IGMS Nasdaq
- HBCP Nasdaq
- Market Cap
- IGMS 348.5M
- HBCP 398.8M
- IPO Year
- IGMS 2019
- HBCP 2008
- Fundamental
- Price
- IGMS $1.77
- HBCP $46.51
- Analyst Decision
- IGMS Hold
- HBCP Buy
- Analyst Count
- IGMS 8
- HBCP 2
- Target Price
- IGMS $6.14
- HBCP $46.50
- AVG Volume (30 Days)
- IGMS 779.9K
- HBCP 25.4K
- Earning Date
- IGMS 03-06-2025
- HBCP 01-27-2025
- Dividend Yield
- IGMS N/A
- HBCP 2.24%
- EPS Growth
- IGMS N/A
- HBCP N/A
- EPS
- IGMS N/A
- HBCP 4.51
- Revenue
- IGMS $2,918,000.00
- HBCP $130,219,000.00
- Revenue This Year
- IGMS $23.57
- HBCP N/A
- Revenue Next Year
- IGMS $192.36
- HBCP $4.77
- P/E Ratio
- IGMS N/A
- HBCP $10.31
- Revenue Growth
- IGMS 57.64
- HBCP N/A
- 52 Week Low
- IGMS $1.59
- HBCP $33.30
- 52 Week High
- IGMS $22.50
- HBCP $52.39
- Technical
- Relative Strength Index (RSI)
- IGMS 19.54
- HBCP 51.75
- Support Level
- IGMS $1.59
- HBCP $44.75
- Resistance Level
- IGMS $2.06
- HBCP $46.33
- Average True Range (ATR)
- IGMS 0.45
- HBCP 1.37
- MACD
- IGMS -0.30
- HBCP 0.19
- Stochastic Oscillator
- IGMS 3.27
- HBCP 89.82
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About HBCP Home Bancorp Inc.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities. The principal sources of funds are customer deposits, repayments of loans, repayments of investments and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans. Its primary expenses are interest expense on deposits and borrowings and general operating expenses.